ZNF417

Across TCGA pan-cancer cohorts, ZNF417 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZNF417 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher ZNF417 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF417 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, UCEC, and LIHC are the cancer types where ZNF417 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	IV	0.074	0.496	.002	12	view →
UCEC	DFS	Median	All	0.962	0.617	.010	12	view →
LIHC	OS	Median	All	0.152	0.688	.017	9	view →
READ	DFS	Median	II,III,IV	0.112	0.800	.002	6	view →
LUAD	OS	Median	II,III,IV	0.017	0.678	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZNF417–STAD (OS)

Open the STAD breakdown →